SUPPLEMENT TO PROXY STATEMENT
FOR THE 2019 ANNUAL MEETING OF STOCKHOLDERS
To Be Held On May 30, 2019
We are furnishing to you this supplement to our proxy statement, dated May 23, 2019 (this Supplement), to supplement the
Notice of Annual Meeting and Proxy Statement, dated April 22, 2019 (the Proxy Statement), with respect to the solicitation of proxies by the Board of Directors of Dynavax Technologies Corporation for use at the 2019 Annual Meeting
of Stockholders, to be held on Thursday, May 30, 2019 at 9:00 a.m., Pacific Time, at the Companys executive offices at 2929 Seventh Street, Suite 100, Berkeley, California 94710.
The purpose of this Supplement is to provide information relating to recently announced changes to our management team and our Board of
Directors, and in the compensation arrangements of certain of our executive officers.
This Supplement should be reviewed together with
the Proxy Statement. Except as described in this Supplement, the information provided in the Proxy Statement continues to apply and should be considered in voting your shares of Dynavax common stock. To the extent that the information in this
Supplement differs from or updates the information contained in the Proxy Statement, the information in this Supplement is more current and supersedes that information contained in the Proxy Statement.
In this Supplement, terms such as we, us and our refer to Dynavax Technologies Corporation, which may also
be referred to from time to time as Dynavax or the Company.
MANAGEMENT CHANGES
CEO Retirement
On
May 20, 2019, Eddie Gray, the Companys Chief Executive Officer and a member of the Companys Board of Directors (the
Board
), submitted notice of his retirement from the Company, including the Board, effective
August 1, 2019. The Company has commenced a search process for a successor Chief Executive Officer.
Appointment of
Co-Presidents
On May 21, 2019 the Board appointed, on an interim basis, David Novack and Ryan
Spencer as
Co-Presidents
of the Company. In these roles, they will also act as
co-principal
executive officers of the Company, effective immediately.
Mr. Novack joined Dynavax in March 2013 as Senior Vice President, Operations and Quality. Mr. Novack was formerly with Novartis
Vaccines & Diagnostics where he served since 2009 as the Global Head of Technical Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis,
Mr. Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr. Novack worked at MedImmune, formerly Aviron, serving in several capacities including business
development, manufacturing, contract operations and most recently as Senior Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr. Novack was with American Cyanamid Company in various roles. Mr. Novack received a B.S. in
Biology from State University of New York and an M.B.A. from Columbia University.
Mr. Spencer joined Dynavax in 2006. Since then, he
held a variety of positions with increasing responsibility, including his current role as Senior Vice President, Commercial. Prior to joining Dynavax, Mr. Spencer was the Assistant Controller at QRS Corporation, a publicly-held technology
company, and was a member of the audit practice at Ernst & Young. Mr. Spencer earned a B.A. in Business Economics from University of California, Santa Barbara.